A Post-marketing Study Evaluating the Presence and Concentration of BRIUMVI™ in Breast Milk (PROVIDE)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Maternal Criteria:

• Participant has independently decided to be treated with BRIUMVI™ prior to providing consent to participate in the study

• Diagnosis of RMS, to include clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS)

• Willing to breastfeed or pump regularly during the study period to maintain milk supply and exclusively pump breast milk for the 24-hour period of breast milk collection Day 1 post IV dose

• Plans to continue feeding infant breast milk at least throughout the duration of the study and is not weaning

⁃ Infant Criteria:

• Gestational age at delivery ≥35 weeks

• Birthweight \> 10th percentile

• Weight \> 10th percentile as reported by the mother at the time of enrollment

Locations
United States
California
PROVIDE Virtual Research Coordination Center
RECRUITING
San Francisco
Georgia
PROVIDE Virtual Research Coordination Center
RECRUITING
Smyrna
North Carolina
PROVIDE Virtual Research Coordination Center
RECRUITING
Wilmington
Contact Information
Primary
PROVIDE Virtual Research Coordination Center
briumvi_lactationstudy@ppd.com
1-877-296-4411
Time Frame
Start Date: 2024-03-26
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 16
Treatments
Breast Milk Collection
Breast milk will be collected of participants with relapsing forms of multiple sclerosis (RMS) who are receiving BRIUMVI™ therapeutically for up to 24 hours to determine concentration of BRIUMVI™ in milk samples.
Sponsors
Leads: TG Therapeutics, Inc.

This content was sourced from clinicaltrials.gov